… Despite the similar overall toxicity profile, CET and PANI … toxicities associated with each
single anti-EGFR agent and eventually find possible differences in the incidence of skin toxicities…

… Possible cetuximab effects on healthy tissues responsible for skin toxicity (C) Acquired resistance
to cetuximab… to cetuximab. (D) Combined treatment with ICI. Possible synergy between …

… cutaneous toxicity related to treatment with the anti-EGFR monoclonal antibody, cetuximab.
… grading of the severity of skin toxicity induced by cetuximab, with some advantages over the …

… skin toxicity AND head neck cancer AND cetuximab AND Radiotherapy (Radiation therapy,
Radiation). The review of the literature was restricted to articles published between February …

… locally advanced cutaneous squamous cell cancers (laCSCC) … Cetuximab has activity in
other EGFR expressing cancers … with laCSCC treated with cetuximab induction and concurrent …

… cetuximab with lenalidomide for the treatment of advanced colorectal and head and neck
squamous cell cancers (… escalation for cetuximab, but dose reductions were allowed for toxicity. …

… 3 toxicity. A greater proportion of patients with early skin toxicity than patients without this
toxicity … Multivariate analysis identified early skin toxicity as an independent predictor of better …

… cancer (CRC), the understanding and management of their associated clinical toxicities are
… We believe that a thorough recognition of the toxicities of EGFR mAb drugs is essential for …

… In addition, the mean serum IL-1β level at 24 h after cycle 1 in patients with skin toxicity
was lower than that in patients without skin toxicity. Previous reports have shown that the …

… cetuximab-related skin toxicity and early tumor shrinkage on overall survival in patients treated
with FOLFIRI plus cetuximab… during cycles 1–3 of treatment with FOLFIRI plus cetuximab. …